<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Newest Pathogenetic Considerations in Inclusion-body Myositis: Possible Role of Amyloid-β, Cholesterol, Relation to Aging and to Alzheimer&apos;s Disease</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Valerie</forename><surname>Askanas</surname></persName>
							<email>askanas@hsc.usc.edu</email>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">W</forename><surname>King Engel</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Address University of Southern California Neuromuscular Center</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Good Samaritan Hospital</orgName>
								<address>
									<addrLine>637 South Lucas Avenue</addrLine>
									<postCode>90017-1912</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Newest Pathogenetic Considerations in Inclusion-body Myositis: Possible Role of Amyloid-β, Cholesterol, Relation to Aging and to Alzheimer&apos;s Disease</title>
					</analytic>
					<monogr>
						<idno type="ISSN">1523-3774</idno>
					</monogr>
					<idno type="MD5">FFE32004271A97AA9C00224374887EAB</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Sporadic inclusion-body myositis (s-IBM) is the most common, progressive, and debilitating muscle disease of older persons [1••,2••]. This report concentrates on new concepts of the pathogenesis of s-IBM.</p><p>The term hereditary inclusion-body myopathies (h-IBMs) <ref type="bibr" target="#b4">[3]</ref> designates hereditary muscle diseases with pathology strikingly resembling that of s-IBM, but lacking lymphocytic inflammation. The h-IBMs are not discussed in this report, but there is a recent review <ref type="bibr" target="#b5">[4]</ref>.</p><p>An intriguing aspect of the s-IBM muscle-fiber molecular phenotype is its remarkable similarity to that of Alzheimer's disease (AD) brain [1••]. These similarities include accumulations of amyloid-β precursor protein (AβPP), amyloid-β (Aβ), phosphorylated tau in the form of paired-helical filaments (PHFs), presenilin-1, and several other "Alzheimer-characteristic proteins" [1••].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Brief Summary of Clinical Features</head><p>The onset of s-IBM is usually after age 50 years, predominantly in men [1••,2••,5]. The muscle weakness is distal and proximal in the lower and upper limbs. The quadriceps is prominently involved [1••,5,6•]. The slowly progressive course of s-IBM usually leads to severe disability and eventually to respiratory muscle weakness. Dysphagia is fairly common.</p><p>The "late-juvenile" s-IBM (LJ-sIBM) form <ref type="bibr" target="#b9">[7]</ref> was recently observed in three young unrelated men with a similar distribution of muscle weakness to that of s-IBM, but with onset in their late teens (two patients) and at age 20 (one patient). Their muscle biopsy had features of s-IBM, with some aspects of h-IBM. Askanas and Engel <ref type="bibr" target="#b9">[7]</ref> proposed that yet-unknown susceptibility genes may be responsible for the early onset of s-IBM in these patients.</p><p>Sporadic inclusion-body myositis is rarely associated with other systemic disorders. However, the following associations deserve mention because they may provide clues to the pathogenesis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sporadic inclusion-body myositis and transthyretin gene mutation</head><p>Askanas et al. <ref type="bibr">[8•</ref>] recently described a 70-year-old African-American man who has s-IBM and cardiac amyloidosis and is homozygous for the transthyretin (TTR) Val122Ile mutation. Unique pathologic features of his muscle biopsy included prominent blood-vessel congophylic amyloid immunoreactive for transthyretin and, within the vacuolated muscle fibers, congophilic deposits co-immunoreactive for transthyretin and Aβ.</p><p>This report summarizes clinical features and diagnostic criteria, and the newest advances related to seeking the pathogenic mechanism(s) of sporadic inclusion-body myositis. On the basis of the authors' research, several processes seem to be important in relation to the still-speculative pathogenesis: increased transcription and accumulation of amyloid-β precursor protein and accumulation of its proteolytic fragment amyloid-β; abnormal accumulation of components related to lipid metabolism (eg, low-density lipoprotein receptors and cholesterol; accumulation of cholestorol is possibly caused by its abnormal trafficking); oxidative stress; accumulations of other Alzheimer-related proteins including phosphorylated tau; a milieu of muscle cellular aging in which these changes occur. The authors' basic hypothesis is that overexpression of amyloid-β precursor protein within the aging muscle fibers is an early upstream event causing the subsequent pathogenic cascade. The remarkable pathologic similarities between inclusion-body myositis muscle and Alzheimer's disease brain are discussed.</p><p>The TTR Val122Ile mutation is the most common cause of senile cardiac amyloidosis among African-Americans <ref type="bibr" target="#b12">[9]</ref>. Askanas et al. <ref type="bibr">[8•]</ref> suggest that the TTR mutation in their patient might be promoting the amyloid-fibrillogenesis of Aβ within the muscle fibers and muscle blood vessels. In this particular patient, the senile cardiac amyloidosis, muscle blood-vessel amyloidosis, and s-IBM all possibly relate to the TTR mutation, raising the possibility that other, possibly-benign mutations of various susceptibility genes may promote s-IBM in other patients. If the TTR Val122Ile mutation was a factor in the s-IBM pathogenesis in our patient, then it had existed since conception, but his muscle weakness did not develop until after the age of 60, suggesting the importance of an aging cellular environment for development of s-IBM (as described in this report).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sporadic inclusion-body myositis and post-polio syndromes</head><p>Sporadic inclusion-body myositis in post-polio patients has been described <ref type="bibr" target="#b6">[5]</ref>, raising possibility that the previous virus infection in some manner was related to the patients' subsequent development of s-IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sporadic inclusion-body myositis and human T-cell leukemia virus-1 seropositivity</head><p>Several patients with s-IBM had human T-cell leukemia virus-1 (HTLV-1) seropositivity and s-IBM, raising suspicion that this virus may cause s-IBM and supporting our general hypothesis that s-IBM may have a viral aspect of its pathogenesis [1••,5,6•,10]. In one of the patients, HTLV-1 p19 antigen was detected immunocytochemically within the muscle fibers <ref type="bibr" target="#b14">[11]</ref>. A recently reported patient with s-IBM and HTLV-1 associated myelopathy had IBM-characteristic muscle fibers containing the proviral DNA and viral messenger ribonucleic acid (mRNA) transcripts <ref type="bibr">[12••]</ref>. In other patients with s-IBM seropositive for HTLV-1, no HTLV-1 antigen was detectable in the muscle fibers <ref type="bibr" target="#b16">[13]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Others</head><p>Rare associations of s-IBM with other syndromes have been reported and reviewed <ref type="bibr" target="#b6">[5]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic Criteria of the Sporadic Inclusion-body Myositis Muscle Biopsy</head><p>Light-microscopic histochemistry and immunocytochemistry Characteristic features of s-IBM are muscle fibers with one or several vacuoles on a given 10-µm thick cross-section and degrees of lymphocytic inflammation, with some macrophages, varying from abundant in early stages to little or none in later stages of involvement of the sampled muscle. Sixty percent to 80% of the s-IBM vacuolated muscle fibers contain, mainly in their non-vacuolated regions, foci of amyloid as defined by Congo-red fluorescence visualized through Texas-red filters <ref type="bibr" target="#b17">[14]</ref>.</p><p>To diagnose s-IBM, the authors recommend the following performed on 10-µm sections of a fresh-frozen muscle biopsy: 1) Engel-Gomori trichrome stain to visualize, in addition to mononuclear-cell inflammation and vacuolated muscle fibers, small angular fibers, ragged-red fibers, rare necrotizing fibers and regen-degen fibers; 2) fluorescence-enhanced Congo-red; 3) SMI-31 monoclonal antibody immunocytochemical staining, which recognizes the phosphorylated tau of PHFs in s-IBM <ref type="bibr" target="#b18">[15]</ref>; 4) if SMI-31 antibody is not available, then ubiquitin immunoreactivity within muscle fibers of s-IBM can be used to differentiate it from polymyositis <ref type="bibr" target="#b19">[16,</ref><ref type="bibr" target="#b20">17]</ref>.</p><p>Mitochondria abnormalities that are characteristic but not diagnostic features of the s-IBM pathology include ragged-red fibers and cytochrome-c-oxidase (COX) negative muscle fibers [1••,5]. Multiple mitochondrial DNA deletions <ref type="bibr" target="#b21">[18,</ref><ref type="bibr" target="#b22">19]</ref> occur in s-IBM muscle. The authors propose that overexpression of AβPP/Aβ may contribute to the mitochondrial abnormalities <ref type="bibr" target="#b23">[20]</ref>. Contribution of the mitochondrial abnormalities to muscle-fiber malfunction and degeneration is yet undefined.</p><p>Small angular muscle fibers, histochemically dark with the pan-esterase or NADH-tetrazolium-reductase reactions, are generally considered indicative of recent-denervation. They are a characteristic feature of s-IBM muscle biopsies and probably contribute to the clinical muscle weakness. Askanas and Engel [1••,5] and others consider that there is an important denervation component in s-IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ultrastructural abnormalities</head><p>Characteristic are clusters of 15 to 21 nm diameter PHFs containing phosphorylated tau <ref type="bibr" target="#b18">[15,</ref><ref type="bibr" target="#b24">21]</ref>, located in vacuolated and non-vacuolated muscle fibers, strikingly resembling PHFs of AD brain. The s-IBM muscle-fiber cytoplasm also contains Aβ-positive collections of 6 to 10 nm filaments, fine flocculomembranous material, and amorphous material [1••]. Within the vacuoles, myelin-like whorls, sometimes appearing like "cabbage bodies" <ref type="bibr" target="#b25">[22]</ref>, and other lysosomal debris are characteristically present. Abnormal mitochondria containing paracrystalline inclusions are occasionally present. In 2% to 4% of s-IBM muscle nuclei there are clusters (inclusions) of 15 to 21 nm "tubulofilaments," which in favorable sections are seen to be PHFs like those in the cytoplasm. The nuclear PHFs are sparce, comprising less than 1% of all the muscle-fiber PHFs (Askanas, Unpublished observation).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Newest Concepts of Pathogenesis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General considerations</head><p>The authors' pathologic findings in biopsies of patients with s-IBM have generated several hypotheses related to the pathogenesis of this still-enigmatic muscle disease. s-IBM is probably a multifactorial disease. The direct causes are unknown. Aging factors are likely to be an important component of the s-IBM pathogenesis. The authors have proposed that increased expression of several genes is at least one aspect underlying the demonstrated increase of the respective IBM-characteristic proteins, including accumulation within IBM muscle fibers of several proteins, in addition to AβPP, Aβ, and phosphorylated tau, for example, presenilin-1, α-synuclein, and several other proteins, most of which were previously considered characteristic of AD brain [1••]. Cellular prion protein (PrP C ) and PrP C mRNA are also accumulated in s-IBM muscle fibers [1••], but not in AD brain. It is possible that in s-IBM muscle fibers a detrimental cascade might be started by one "master-gene" product (protein) serving, directly or indirectly, as a transcription factor activating genes for at least some of these "IBM-proteins" [1••]. A putative "IBM" master-gene itself might be activated by a viral gene-product.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overexpression of amyloid-β precursor protein and intracellular accumulation of amyloid-β appear to be early and important steps in the inclusion-body myositis pathogenesis</head><p>Possible mechanisms of amyloid-β precursor protein/amyloid-β increase Amyloid-β and AβPP have received considerable attention regarding the pathogenesis of AD <ref type="bibr" target="#b26">[23,</ref><ref type="bibr" target="#b27">24]</ref>. Aβ and C-and N-terminal epitopes of AβPP are also abnormally accumulated in vacuolated and non-vacuolated regions of s-IBM muscle fibers [1••,2••]. s-IBM muscle fibers have increased mRNA signal for the AβPP-751 alternatively-spliced transcript that contains the Kunitz-type protease inhibitor motif <ref type="bibr" target="#b28">[25]</ref>. The increased AβPP-mRNA co-localizes in the same foci as the abnormal accumulations of AβPP and Aβ immunoreactive epitopes <ref type="bibr" target="#b28">[25]</ref>. The mechanism of AβPP overproduction in s-IBM is not clarified, but our recent studies suggest that the AP-1 transcription complex, composed of c-Jun and c-Fos, may play a role [1••].</p><p>Increased transcription and activation of c-Jun and c-Fos can occur through PKC, JNK and active ERK <ref type="bibr" target="#b29">[26,</ref><ref type="bibr" target="#b30">27]</ref>. Because c-Jun, c-Fos [1••], ERK <ref type="bibr" target="#b31">[28]</ref> and PKC <ref type="bibr">(Askanas et al., unpublished data 2000)</ref> are increased in IBM muscle fibers, they may play a role in the AβPP overexpression.</p><p>Also increased in IBM muscle is Redox-factor-1 (Ref-1) <ref type="bibr" target="#b32">[29]</ref>, a protein possessing apurinic/apyrimidic endonuclease activity and ability to increase the affinity of AP1 for its binding site in the promoter region of several target genes including AβPP, thereby modulating their transcription. Ref-1 also enhances binding of the transcription factor nuclear factor-κB (NFκB) to DNA, thus participating in the increased transcription of several genes, including AβPP. Oxidative stress induces Ref-1 activation <ref type="bibr" target="#b29">[26,</ref><ref type="bibr" target="#b33">30]</ref>. IBM muscle fibers contain increased NFκB <ref type="bibr" target="#b34">[31]</ref> and markers of oxidative stress, which might also be involved in the increased AβPP transcription. RNA polymerase II is also increased in IBM fibers <ref type="bibr" target="#b35">[32]</ref>, another sign suggesting increased transcription activity.</p><p>Recently, the authors have shown that BACE1 and BACE2, which are AβPP β-secretases, are increased within IBM muscle fibers, suggesting that their overproduction may participate in AβPP processing, resulting in the increased Aβ production <ref type="bibr">[33••]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Possible upstream role of amyloid-β precursor protein and amyloid-β in the inclusion-body myositis pathogenesis</head><p>The authors have proposed that key upstream roles of the increased intracellular AβPP/Aβ include causing abnormal signal transduction to modulate other genes; inducing oxidative stress; and producing mitochondrial and other abnormalities [1  <ref type="bibr" target="#b40">[35]</ref>. Third, experimentally and genetically AβPP-overexpressing cultured muscle fibers had abnormal neuromuscular junctions (NMJs) and could not become innervated by co-cultured fetal-rat spinal-cord neurons. Therefore, McFerrin et al. <ref type="bibr" target="#b41">[36]</ref> postulated that spontaneous AβPP overexpression in muscle of patients with s-IBM may be responsible for a "myogenous dysinnervation" and for the observed NMJ structural abnormalities [1••]. The neuromuscular synapse pathology in IBM has a parallel in the synapse pathology of AD <ref type="bibr" target="#b42">[37]</ref>, which, by analogy with IBM, the authors propose may reflect an intracellular postsynaptic pathogenic mechanism.</p><p>Most of the "IBM proteins" and "IBM mRNAs" that are accumulated in IBM muscle fibers are, in normal mature human muscle fibers, found only at the postsynaptic region of the NMJs <ref type="bibr" target="#b43">[38]</ref>. (Phosphorylated tau is the only "IBM protein" so far not found accumulated at normal NMJs <ref type="bibr" target="#b43">[38]</ref>.) Askanas et al. [1••,5,38] termed the normal accumulation of protein and mRNA postsynaptically at the NMJ as "junctionalization" of the muscle fiber. The authors proposed a possible pathogenic role of "extrajunctionalization" in IBM muscle fibers, driven by ectopic expression of "junctional genes," perhaps under the unrestrained control of a "junctionalizing master gene."</p><p>Additional support of the authors' intracellular AβPP/ Aβ hypothesis of IBM pathogenesis was provided by two transgenic mouse models overexpressing AβPP in muscle fibers <ref type="bibr" target="#b44">[39,</ref><ref type="bibr" target="#b45">40]</ref>. In both models, some aspects of the IBM pathology were produced, including fiber vacuolization, intracellular accumulation of AβPP, intracellular amyloid deposits and inflammation <ref type="bibr" target="#b44">[39,</ref><ref type="bibr" target="#b45">40]</ref>. These abnormalities were evident only in aging transgenic mice, further indicating that an aging cellular environment is important for the development of IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Lipoprotein receptors, cholesterol, and related mechanisms in the inclusion-body myositis pathogenesis</head><p>The low-density-lipoprotein-receptor (LDLR) gene superfamily encompasses several transplasmalemmal receptors, including LDLR, very-low-density-lipoprotein-receptor (VLDLR) and LDLR-related protein (LRP) <ref type="bibr" target="#b46">[41,</ref><ref type="bibr" target="#b47">42]</ref>. The best-known function of the LDLR family is binding and delivery of lipoproteins into cells <ref type="bibr" target="#b46">[41,</ref><ref type="bibr" target="#b47">42]</ref>. Other possibly relevant aspects of the LDLR family members are as follows: 1) They bind and internalize apolipoprotein E (apoE) <ref type="bibr" target="#b46">[41]</ref>; 2) LRP influences processing of AβPP and Aβproduction in cell-culture systems <ref type="bibr" target="#b48">[43]</ref>; 3) VLDLR might influence tau phosphorylation; 4) they are accumulated in extracellular senile plaques of AD brain <ref type="bibr" target="#b49">[44</ref> suggesting the following: 1) that the dissociation of apoE from its LDL receptors that normally follows endocytosis <ref type="bibr" target="#b46">[41]</ref> might be inhibited in IBM; 2) that apoE with its receptor becomes trapped within the IBM muscle fibers, possibly as a result of the known ability of apoE to bind to Aβ and tau <ref type="bibr" target="#b51">[45]</ref>; or 3) that apoE, LDLR, and VLDLR each bind independently to Aβ and phosphorylated-tau.</p><p>Cholesterol is a component of native apoE-containing lipoprotein particles <ref type="bibr" target="#b52">[46]</ref>. The authors recently showed that IBM muscle fibers contained accumulations of free (non-esterified) cholesterol that colocalized with LDLR and VLDLR immunoreactive inclusions, and with Aβ and phosphorylated tau <ref type="bibr">[44••]</ref>. This suggested that in IBM muscle fibers accumulation of free cholesterol may represent another consequence, in addition to apoE accumulation, of the increased expression and ectopic accumulation of LDLR and VLDLR <ref type="bibr">[44••]</ref>. Most recently Kefi et al. <ref type="bibr" target="#b53">[47]</ref> demonstrated that caveolin-1, an intracellular transporter of cholesterol, is accumulated in IBM muscle fibers, where it colocalizes with free cholesterol and Aβ. Caveolin-1, a major protein of plasmalemmal microdomain caveolae, binds cholesterol and influences its intracellular traffic and homeostasis <ref type="bibr" target="#b54">[48]</ref>. The authors suggest that within IBM muscle fibers traffic of cholesterol is perturbed, resulting in its demonstrated accumulation there <ref type="bibr" target="#b53">[47]</ref>. In normal mammalian brain and various types of cultured cells, AβPP and Aβ are concentrated in the cholesterol-rich domains of the plasmalemma and intracellular membranes <ref type="bibr" target="#b55">[49]</ref>. Experimentally, cholesterol influences AβPP processing, resulting in increased Aβ production, and it increases Aβ amyloidogenesis <ref type="bibr" target="#b56">[50,</ref><ref type="bibr" target="#b57">51]</ref>. Loading cultured cells with free cholesterol increased generation of Aβ from AβPP, whereas cholesterol-depletion did the opposite <ref type="bibr">[44••]</ref>. The mechanism by which cholesterol influences AβPP processing is unknown, but one possibility may involve direct or indirect inhibition of an AβPP α-secretase [44••]. Cholesterol binds to Aβ <ref type="bibr" target="#b57">[51]</ref> and, by altering Aβ conformation, enhances its amyloidogenic ("seeding") properties <ref type="bibr">[44••]</ref>. Experimentally-induced abnormal intracellular trafficking of cholesterol in cultured cells, either pharmacologically or by inactivation of a gene encoding Niemann-Pick type C-1 protein (a protein that is mutated in Niemann-Pick type C disease), causes co-accumulation of aggregated Aβ and free cholesterol in the same intracellular deposits <ref type="bibr">[44••]</ref>.</p><p>The authors propose that within IBM muscle fibers cholesterol, instead of being properly metabolized or cleared, is deposited, in spatial association with lipoprotein receptors, apoE and caveolin-1, at sites of Aβ accumulation and possibly at sites of AβPP processing. At those sites, cholesterol might be increasing Aβ production and inducing Aβ amyloidogenesis. The authors' hypothetical considerations of cholesterol and Aβ interactions in IBM are illustrated in Figure <ref type="figure" target="#fig_1">1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Oxidative stress has a possible influence in the pathogenic cascade of inclusion-body myositis</head><p>There is increasing evidence that free-radical toxicity may participate in the IBM pathogenesis. Indicators of oxidative stress, and enzymes participating in the cellular defense against oxidative stress, are accumulated in IBM muscle fibers [1••].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Role of inflammation and autoimmunity</head><p>Mononuclear-cell inflammation is a component of s-IBM pathology. The inflammation varies from abundant in the early stages to little or none in the mid-and later stages of the muscle involvement. The mononuclear inflammatory cells are similar to those in polymyositis (PM), being mainly CD8 + cytotoxic T-cells and some macrophages </p><formula xml:id="formula_0">-induced [1••,2••],</formula><p>in neither s-IBM nor PM is a putative antigen known. Considerations include an antigen of a yet-unidentified virus <ref type="bibr" target="#b58">[52]</ref>, an auto-antigen, or a superantigen phenomenon <ref type="bibr" target="#b58">[52]</ref>. Other aspects of the s-IBM immune reactions have recently been reviewed <ref type="bibr">[53•,54•]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Muscle-fiber aging as a likely aspect contributing to development of sporadic inclusion-body myositis</head><p>Sporadic inclusion-body myositis typically becomes clinically manifest after age 50, and more often in the 60s and 70s. Among patients with sporadic "inflammatorymyopathy," the previously described specific degenerative accumulations of proteins, mRNAs, and cholesterol within muscle fibers occur only in s-IBM, not in polymyositis or dermatomyositis. But they do occur in the h-IBMs, which typically lack the lymphocytic inflammatory component <ref type="bibr" target="#b4">[3,</ref><ref type="bibr" target="#b5">4]</ref>. The authors suggest those accumulations are related to an aging-based degenerative pathogenic cascade that 1) occurs in parallel to the inflammatory component but is not dependent on it; 2) persists longer than the inflammatory component at a given site in the muscle; and 3) will require a treatment other than anti-dysimmune. (Speculatively, in s-IBM, muscle-fiber degenerative phenomena might provoke the inflammatory response, which gradually diminishes as the immune system becomes tolerant, or perhaps the degenerative phenomena and the inflammation are independently provoked by something else, such as occult virus or one of the "foreign" accumulated proteins.) Patients over age 50 with what could be considered "pure PM" are rare. Virtually all of the older patients with lymphocytic myositis have s-IBM. In s-IBM the milieu of the aging muscle fiber might modify the provocation of, and response to, the lymphocytic inflammation and promote development of the IBM-characteristic progressive vacuolar degeneration [1••].</p><p>Aging changes within muscle mitochondria <ref type="bibr" target="#b62">[55]</ref> or elsewhere in the muscle fiber may predispose to the mitochondrial abnormalities in s-IBM, provoking a vicious circle between mitochondrial malfunctions and the oxidative stress evident in the fiber. In the cellular milieu of the aging muscle-fiber, there may be diminished homeostatic mechanisms caused by either underexpression of "youthful" genes encoding beneficial cellular factors or overexpression of yet-unknown "aging" genes encoding toxic cellular fac-tors. Such aging mechanisms may predispose to, or underlie, the muscle-fiber vacuolar-degeneration, atrophy and cell death in s-IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Possible relevance of morpho-chemical similarities between inclusion-body myositis muscle and Alzheimer's disease brain</head><p>Because the same proteins accumulate within sporadic and hereditary IBM muscle fibers as accumulate in the brain of sporadic and hereditary forms of AD [1••], the muscle and the brain diseases might share certain steps in their pathogenic cascade, and knowledge of one disease might help elucidate the other. Cellular aging and evidence of oxidative stress are associated with the IBMs and ADs [1••]. The IBMs and the ADs (including sporadic and hereditary forms of both groups) are multifactorial and polygenetic. Within the IBM and AD categories, the pathologic phenotypes of sporadic and hereditary forms are very similar, despite the different direct causes being mainly non-genetic versus mainly genetic. Therefore, in each disease category it has been proposed, by the authors in the IBMs and by others in the ADs [1••], that different etiologies, including different genetic defects in the hereditary forms, lead to the same upstream step that promotes a midstream and downstream final common pathogenic cascade of events resulting in the specific cellular deterioration. Yet each disease category, IBM and AD, remains organ-specific, involving postmitotic-muscle fibers or post-mitotic-neurons. The tissue selected in the sporadic forms, muscle versus brain, may be influenced by etiologic agent (eg, virus), previous exposure to an </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>The authors have presented their newest findings and approaches to the pathogenesis of s-IBM.</p><p>These findings have not yet provided a denouement of the cause and definitive treatment, but they have illuminated new, potentially exciting avenues to explore that could lead to long-term benefit for patients with IBM. A few patients with s-IBM definitely benefit, to some degree, from treatment with single-dose alternate-day prednisone or intravenous immunoglobin G ( <ref type="bibr" target="#b13">[10]</ref> and Engel, current observations). In those responsive patients, the component being therapeutically regulated is not certain. It could be the mononuclear inflammatory cells in the muscle, the muscle-fiber degenerative changes, a dysimmune neuropathy, or a myogenous dysinnervation. However, much better treatment is certainly needed.</p><p>The authors have indicated the remarkable pathologic similarities between s-IBM muscle and AD brain. In AD, the toxicity of Aβ (or its fragments) has been thought by others to be extracellular <ref type="bibr" target="#b26">[23]</ref>. Because in IBM the authors have considered that Aβ toxicity is intracellular [1••], in 1998 Askanas and Engel <ref type="bibr" target="#b63">[56]</ref> proposed a similar intracellular mechanism for AD. This is now also being considered by some of the AD researchers <ref type="bibr" target="#b64">[57]</ref>.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>[1••,2••]. In s-IBM and PM there is a predominance of CD45 RO + memory T-cells in endomysial infiltrates [1••,2••]. The cause of the lymphocytic mononuclear-cell inflammation in s-IBM is unknown. Although the type of T-cell response suggests it is antigen</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc>Figure 1. Possible interactions and consequences of amyloid-β precursor protein, amyloid-β, cholesterol, and caveolin-1 in inclusion-body myositis muscle fibers. Aβ-amyloid-β; AβPP-amyloid-β precursor protein; PHF-paired-helical filament.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc>••]. (The recent concept of a putative toxicity of small oligomeric aggregates of Aβ in AD [34••] could also apply intracellularly to IBM.) The authors' hypothesis concerning the pathogenic importance of AβPP and Aβ is supported by several studies. First, the experimental overexpression of AβPP through direct Aβ PP gene transfer into human normal, aneurally-cultured muscle fibers induced most of the basic aspects of the IBM phenotype, including vacuolation, intracellular congophilia, accumulation of Aβ in 6 to 10 nm fibrils, nuclear PHFs (cytoplasmic PHFs have not yet been observed) and abnormal mitochondria [1••]. Second, in h-IBM cultured muscle fibers, the genetically-determined AβPP overexpression preceded other IBM-like abnormalities</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc>••]. apoE is prominently accumulated in IBM muscle fibers, colocalizing with Aβ and phosphorylated tau [1••]. apoE also colocalizes with the accumulated LDLR and VLDLR [44••],</figDesc><table /></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>The authors' studies described in this review were supported in part by the National Institutes of Health (grants NS34103 and AG16768), the Muscular Dystrophy Association and Alzheimer Foundation, and the Helen Lewis, Sheldon Katz, and Ron Stever Research Funds. The authors are grateful to their research and clinical colleagues and staff for their participation in various aspects of these studies.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Recommended Reading Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance 1.•• Askanas V, Engel WK: Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease</title>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">A detailed description of abnormal accumulations of various proteins in sporadic inclusion-body myositis muscle fibers and their pathogenetic significance</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: genetic factors, aberrant protein expression, and autoimmunity</title>
		<author>
			<persName><forename type="first">••</forename><surname>Oldfors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fyhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="469" to="475" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">A very good summary of abnormalities found in inclusion-body myositis muscle fibers</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">New advances in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="732" to="741" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Hereditary Inclusion-Body Myopathies. In The Molecular and Genetic Basis of Neurologic and Psychiatric Disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Prusiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dimauro</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2002">2002</date>
			<publisher>In press</publisher>
			<pubPlace>Woburn, MA</pubPlace>
		</imprint>
	</monogr>
	<note>3rd Edition</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecularpathologic similarities to Alzheimer disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion-Body Myositis and Myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>United Kingdom</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<biblScope unit="volume">1998</biblScope>
			<biblScope unit="page" from="3" to="78" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Cala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Thickbroom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1526" to="1534" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">An important paper stressing the validity of MRI to identify the distribution of muscle involvement in sporadic inclusion-body myositis</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Late-juvenile sporadic inclusion body myositis: a newly recognized syndrome</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="439" to="440" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Vall22Ile Allele</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="544" to="549" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">An important paper emphasizing a possible involvement of susceptibility genes in the development of sporadic inclusion-body myositis</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Pastore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yaghoubian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="466" to="473" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanism: personal experience</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion-Body Myositis and Myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>United Kingdom</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="351" to="382" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Sporadic inclusionbody myositis (s-IBM) in an HTLV-I-positive Iranian Muslim</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haginoya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page">124</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">First demonstration of human T-cell leukemia virus type 1 messenger ribonucleic acid in muscle of a patient with sporadic inclusion-body myositis and human T-cell leukemia virus type 1 seropositivity</title>
		<author>
			<persName><forename type="first">S</forename><surname>•• Ozden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gessain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Gout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mikol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="510" to="514" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Inclusion body myositis in HIV -1 and HTLV-1 infected patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cupler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leon-Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1887" to="1893" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Enhanced detection of congo-red positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer disease using fluorescence technique</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1265" to="1267" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Use of antineurofilament antibody to identify paired-helical filaments in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="389" to="391" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Immunocytochemical localization of ubiquitin in inclusion-body myositis allows its light-microscopic distinction from polymyositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Serdaroglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="460" to="461" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Prayson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="887" to="892" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Santorelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sciacco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tanji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="789" to="795" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Analysis of multiple mitochondrial DNA deletions in inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Moslemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mutat</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="381" to="386" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baque</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1314" to="1319" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="774" to="786" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Diseased human muscle in tissue culture: a new approach to the pathogenesis of human neuromuscular disorders</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Pathogenesis of the Human Muscular Dystrophies</title>
				<editor>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Rowland</surname></persName>
		</editor>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>American Elsevier Publishing Co</publisher>
			<biblScope unit="volume">1977</biblScope>
			<biblScope unit="page" from="856" to="871" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Selkoe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Cell Biol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="447" to="453" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Rosenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="2045" to="2054" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">␤-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle</title>
		<author>
			<persName><forename type="first">E</forename><surname>Sarkozi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="815" to="818" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">A direct role for protein kinase C and the transcription factor Jun/AP-1 in the regulation of the Alzheimer&apos;s β-amyloid precursor protein gene</title>
		<author>
			<persName><forename type="first">J</forename><surname>Trejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Massamiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Deng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="21682" to="21690" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">New insights into the regulation of protein kinase C and novel phorbol ester receptors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kazanietz</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999">1999</date>
			<publisher>FASEB</publisher>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1658" to="1676" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Association of active extracellular signal-regulated protein kinase with paired helical filaments of inclusion-body myositis muscle suggests its role in inclusion-body myositis tau phosphorylation</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Wilczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="1835" to="1840" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Redox factor-1 in muscle biopsies of patients with inclusion-body myositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Broccolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">AP-1 function and regulation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Karin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Zandi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Cell Biol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="240" to="246" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Immunolocalization of transcription factor NF-κB in inclusion-body myositis muscle and at normal human neuromuscular junctions</title>
		<author>
			<persName><forename type="first">C-C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="page" from="77" to="80" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Expression of RNA polymerase II and its colocalization with phosphorylated tau in abnormal muscle fibers of sporadic inclusion-body myositis (s-IBM)</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Wilczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page">A241</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusionbody myositis</title>
		<author>
			<persName><forename type="first">••</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="1962" to="1964" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">The first identification of increased expression of BACE1 and BACE2 and their co-localization with amyloid−β in abnormal muscle fibers of sporadic inclusion-body myositis</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Targeting small Abeta oligomers: the solution to an Alzheimer&apos;s disease conundrum?</title>
		<author>
			<persName><forename type="first">••</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Krafft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Finch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Neurosci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="219" to="224" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">An interesting paper stressing the importance of amyloid−β oligomers in the pathogenesis of Alzheimer disease</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cultured muscle fibers from Iranian Jewish patients with quadriceps-sparing autosomalrecessive inclusion-body myopathy (AR1-IBM) express features of IBM phenotype</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page">A438</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="3201" to="3205" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Terry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1023" to="1025" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Fourteen newly recognized proteins at the human neuromuscular junctions-and their non-junctional accumulation in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">841</biblScope>
			<biblScope unit="page" from="28" to="56" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Transgenic mice overexpressing the C-99 fragment of betaPP with an alpha-s myopathy similar to human inclusion body myositis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Hearn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Ogburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1679" to="1686" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fukuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1687" to="1693" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The mammalian lowdensity lipoprotein receptor family</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Hussain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Strickland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bakillah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Nutr</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="141" to="172" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Familial hypercholesterolemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hobbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Scriver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Beaudet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Sly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Metabolic and Molecular Bases of Inherited Disease</title>
				<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>McGraw-Hill</publisher>
			<date type="published" when="2001">2001</date>
			<biblScope unit="page" from="2863" to="2913" />
		</imprint>
	</monogr>
	<note>8th ed</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Modulation of betaamyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP): evidence that LRP contributes to the pathogenesis of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Ulery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Mikhailenko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">275</biblScope>
			<biblScope unit="page" from="7410" to="7415" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle</title>
		<author>
			<persName><forename type="first">••</forename><surname>Jaworska-Wilczynska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wilczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="438" to="445" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">The first identification of accumulated lipoprotein receptors and cholesterol in abnormal muscle fibers in human muscle disease</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Saunders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="751" to="758" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Mahley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Rall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Scriver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Beaudet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Sly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Metabolic and Molecular Bases of Inheritied Disease</title>
				<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>McGraw-Hill</publisher>
			<date type="published" when="2001">2001</date>
			<biblScope unit="page" from="2863" to="2913" />
		</imprint>
	</monogr>
	<note>8th ed</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Abnormal accumulation of caveolin-1 and its co-localization with cholesterol, amyloid-␤ and phosphorylated tau in inclusion-body myositis (IBM) muscle</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kefi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A391</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Cholesterol and caveolae: structural and functional relationships</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Fielding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">1529</biblScope>
			<biblScope unit="page" from="210" to="222" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Emerging themes in lipid rafts and caveolae</title>
		<author>
			<persName><forename type="first">F</forename><surname>Galbiati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Razani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Lisanti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="403" to="411" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The role of cholesterol in the biosynthesis of beta-amyloid</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Frears</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Walters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1699" to="1705" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Audulov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Chochina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Igbavboa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1746" to="1752" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Leon-Monzon M: Viruses, immunodeficiency, and inclusion-body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Illa</forename><forename type="middle">I</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion-Body Myositis and Myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>United Kingdom</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="275" to="290" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">The molecular and cellular pathology of inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">An interesting review on inflammatory myopathies</title>
				<imprint>
			<date type="published" when="2001">2001</date>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="300" to="306" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">New insights, current concepts in the pathophysiology of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mendell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Immunother</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="12" to="16" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<title level="m" type="main">An interesting review on inflammatory myopathies</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Michikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mallidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="4022" to="4027" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Does overexpression of ␤APP in aging muscle have a pathogenic role and a relevance to Alzheimer&apos;s disease? Clues from inclusion-body myositis, cultured human muscle and transgenic mice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1673" to="1677" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Intraneuronal Abeta42 accumulation in human brain</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Gouras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Naslund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="15" to="20" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
